Network Pharmacology Insights into Broccoli Microgreens for Prostate Cancer

Prostate cancer is a leading malignancy in men, ranking fourth globally and fifth in Indonesia (GLOBOCAN 2020). Conventional therapies, though available, a

Puspita Wijaya, Trina Ekawati Tallei, Lydia Estelina Naomi Tendean, Fatimawali Fatimawali, Grace L. A. Turalaki, Diana Shintawati Purwanto

Heca Journal of Applied Sciences · 2025 · https://doi.org/10.60084/hjas.v3i1.264

Abstract

Prostate cancer is a leading malignancy in men, ranking fourth globally and fifth in Indonesia (GLOBOCAN 2020). Conventional therapies, though available, are limited by high costs, side effects, and resistance, highlighting the need for accessible alternatives. Broccoli microgreens, rich in bioactive compounds, have shown potential in preventing and treating various cancers. This study hypothesized that bioactive compounds in broccoli microgreens interact with molecular targets involved in prostate cancer progression. To test this hypothesis, we employed a network pharmacology-based in silico approach to systematically explore these interactions and identify potential therapeutic mechanisms. Bioactive compounds in broccoli microgreens were identified using liquid chromatography-mass spectrometry (LC-MS) and analyzed via the PubChem database. The biological activities of these compounds were predicted using PASS Online, focusing on their capacity to modulate TP53 gene expression. Pharmacokinetic and toxicity evaluations were performed using ADMETLab 3.0 and Protox 3.0 to assess their safety and drug-like properties. Target proteins were identified through SwissTargetPrediction and GeneCards, while protein-protein interaction networks were constructed using STRING. The pharmacological network was visualized using Cytoscape to elucidate the molecular mechanisms of action. The analysis identified 528 relevant target proteins, with key roles attributed to SRC and EGFR, both critical in resistance to EGFR tyrosine kinase inhibitors and in regulating processes such as cell proliferation, apoptosis resistance, and metastatic potential. Through network pharmacology, bioactive compounds such as kaempferol and polydatin were identified as potential inhibitors of these targets, demonstrating their ability to modulate pathways essential to prostate cancer progression. In conclusion, broccoli microgreens contain bioactive compounds with potential pharmacological relevance for prostate cancer, particularly through their interaction with SRC and EGFR pathways, warranting further experimental validation.

Licence and reuse

LicenceCC-BY-NC-4.0
May we host this PDF?Yes
May we publish a plain-language summary?Yes — this licence permits adaptations.
Commercial use permitted?No — non-commercial use only
Share-alike required?No

How to credit this work

Puspita Wijaya; Trina Ekawati Tallei; Lydia Estelina Naomi Tendean; Fatimawali Fatimawali; Grace L. A. Turalaki; Diana Shintawati Purwanto (2025). Network Pharmacology Insights into Broccoli Microgreens for Prostate Cancer. Heca Journal of Applied Sciences. https://doi.org/10.60084/hjas.v3i1.264 Licensed under Creative Commons Attribution NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/). Hosted by EVEC Athens (microgreens.org.gr). No changes were made to this article. Provided as-is, without warranties. EVEC Athens is not affiliated with, and this copy is not endorsed by, the authors or the publisher.

Explore this on our site

About this copy

This is a copy of the published article, hosted by EVEC Athens for free educational use under its open licence. The permanent scientific reference is the DOI above. We have not altered the file in any way. If you are an author or rights holder and want this copy removed, please use our notice and takedown procedure. We acknowledge every request within five working days, and act within ten.

Co-funded by the European Union.
This portal presents the microgreens methodology; the organisation behind it is EVEC Athens — the European Voluntary and Educational Center (evec.org.gr). Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the European Commission. Neither the European Union nor the granting authority can be held responsible for them.

Open licence. Except where stated otherwise, the educational materials on this portal are licensed under CC BY 4.0 — free to use, adapt and share, including commercially, with credit. See the licence terms.

Accessibility. We aim for WCAG 2.1 AA and publish what does and does not yet meet it — see the accessibility statement. If anything here blocks you, tell us and we will send the material in a format that works for you.